J&J Rx drug sales flat, consumer and devices up

Share this article:
Johnson & Johnson flaunted the benefits of its diversified and global business portfolio today, reporting respectable third-quarter results despite static worldwide pharmaceutical sales of $6.1 billion.

Overall sales were up 6.4% for the quarter, year-on-year, to $15.9 billion. But with the company's prescription drugs business hit by generic competition and overall US sales flat, the growth came from J&J's consumer products and medical device and diagnostics businesses, along with healthy international sales.

Schizophrenia drug Risperdal, in particular, lost US patent protection in June and saw sales slide 62% year-on-year. Long-acting injectable Risperdal Consta, which remains on-patent, saw a 10% jump in sales. Other strong performers among the company's portfolio of prescription drugs included Velcade for multiple myeloma; Remicade for Chron's, rheumatoid arthritis and psoriasis; and Topamax for epilepsy and migranes.

Worldwide consumer sales were up 13.1% to $4.1 billion on a successful US launch of OTC Zyrtec and strong sales of Listerine, Neutrogena, Clean & Clear and Aveeno, as well as international baby care products and Davao, the leading moisturizer in China.

Medical devices and diagnostics sales were up 8.8% for the quarter to $5.7 billion, buoyed by strong performances by J&J Diabetes Care's blood glucose monitoring and insulin delivery products; Ethicon Endo-Surgery's minimally invasive products, Vistakon's disposable contact lenses; Ortho-Clinical Diagnostics' professional products and DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses. However, Cordis sales were hit by new competition and continuing category-wide safety fears in the drug-eluting stent market.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.